Cargando...
Immune targets and neoantigens for cancer immunotherapy and precision medicine
Harnessing the immune system to eradicate malignant cells is becoming a most powerful new approach to cancer therapy. FDA approval of the immunotherapy-based drugs, sipuleucel-T (Provenge), ipilimumab (Yervoy, anti-CTLA-4), and more recently, the programmed cell death (PD)-1 antibody (pembrolizumab,...
Guardado en:
| Publicado en: | Cell Res |
|---|---|
| Autores principales: | , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Nature Publishing Group
2017
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5223235/ https://ncbi.nlm.nih.gov/pubmed/28025978 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cr.2016.155 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|